drugset / Trial / NCT00037596

Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia

NCT00037596

Treatment

Summary

The primary objectives are a) to establish the maximum tolerated dose of gemtuzumab ozogamicin in combination with cytarabine and b) to assess the safety of gemtuzumab ozogamicin when given concurrently with cytarabine.

Timeline

Start
2000-08
Primary completion
2003-04
Completion
2003-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemtuzumab Ozogamicin Monoclonal antibody
Background Cytarabine Small molecule